NEWS BYTES
Lupin and SteinCares enter into license & supply agreement for Ranibizumab in Latin America
Global Pharma major Lupin Limited( Lupin) has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin’ s biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM.
Zydus enters global biologics CDMO business
Zydus Lifesciences announces its entry into the global biologics contract development and manufacturing organization( CDMO) sector through the planned acquisition of Agenus Inc.’ s state-of-the-art biologics manufacturing facilities in California, US. This acquisition positions Zydus at the forefront of the fast-growing global biologics CDMO market.
Sun Pharma discontinues studies of its drug for psoriasis & atopic dermatitis
Sun Pharmaceutical Industries Limited has announced top-line results from the Phase 2 clinical trial evaluating the safety and efficacy of SCD-044( a novel, orally bioavailable sphingosine-1-phosphate( S1P) receptor 1 agonist) for moderate to severe psoriasis. The study did not meet its primary endpoint of 75 % improvement in PASI.
08
BioVoiceNews | June 2025